Mabwell Reveals Encouraging Pre-Clinical Data Of 7MW4811 At The 15Th World ADC Conference

(MENAFN- PR Newswire)

SHANGHAI, Nov. 8, 2024 /PRNewswire/ -- Mabwell (688062), an innovative biopharmaceutical company with entire industry chain, showcased the "Preclinical Development of 7MW4811, an MtoxinTM (MF6)-based Antibody-drug Conjugate for the treatment of Solid Tumors" as a poster presentation at the 15th World ADC San Diego, held from Nov. 4 to 7, 2024. The post revealed compelling data from the studies on the efficacy of 7MW4811 in treating solid tumors.

7MW4811 is developed with Mabwell's next-generation ADC technology (IDDCTM) platform, and has demonstrated encouraging anti-tumor effects across a range of solid tumors, including lung, colorectal, pancreatic and gastric cancers. Notably, it has shown promising therapeutic potentials in gastrointestinal tumors.

IDDCTM is a clinically validated site-specific conjugation technology that has been instrumental in the development of ADCs with good homogeneity, efficacy, and safety profiles. Coupled with the novel payload MtoxinTM (MF6), these ADCs have been furthered optimized, exhibiting enhanced pharmacodynamics, bystander killing efficacy, and anti-multidrug resistance capabilities.

About Mabwell

Mabwell (688062) is an innovation-driven biopharmaceutical company with the entire value chain of the pharmaceutical industry. We provide more effective and accessible therapy and innovative medicines to fulfill global medical needs. Since 2017, an advanced R&D system which covers target discovery, early discovery, druggability, preclinical, clinical research and manufacturing transformation was established. Mabwell has 15 pipeline products in different stages based on a world-class and state-of-the-art R&D engine, including 11 novel drug candidates and 4 biosimilars. We focus on the therapeutic areas of oncology, immunology, bone disorders, ophthalmology, hematology and infectious diseases, etc.
Of these, 3 products have been approved and commercialized, 1 product has been filed for MA, 3 products are in pivotal trials. We have also undertaken 1 national major scientific and technological special project for "Significant New Drugs Development", 2 projects for National Key R&D Programmes, and multiple provincial and municipal science and technological innovation projects.
Mabwell's Taizhou factory possesses robust in-house manufacturing capability compliant with international GMP standards regulated by the NMPA, FDA and EMA, and has passed the EU QP Audit. The large-scale manufacturing base in Shanghai and the ADC commercialized manufacturing base in Taizhou are under construction. Our mission is "Explore Life, Benefit Health" and our vision is "Innovation, from ideas to reality". For more information, please visit .

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company's product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. "Forward-looking statements" are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would," and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company's current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company's control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the potential impact of COVID-19; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

SOURCE Mabwell

MENAFN08112024003732001241ID1108865880